Literature DB >> 19560997

Measurement of the functional status of patients with different types of muscular dystrophy.

Yi-Jing Lue1, Rong-Fong Lin, Shun-Sheng Chen, Yen-Mou Lu.   

Abstract

Muscular dystrophy (MD) comprises a group of diseases characterized by progressive muscle weakness that induces functional deterioration. Clinical management requires the use of a well-designed scale to measure patients' functional status. This study aimed to investigate the quality of the functional scales used to assess patients with different types of MD. The Brooke scale and the Vignos scale were used to grade arm and leg function, respectively. The Barthel Index was used to evaluate the function of daily living activity. We performed tests to assess the acceptability of these scales. The characteristics of the different types of MD are discussed. This was a multicenter study and included patients diagnosed with Duchenne muscular dystrophy (DMD) (classified as severely progressive MD), Becker muscular dystrophy (BMD), limb girdle muscular dystrophy (LGMD) and facioscapulohumeral muscular dystrophy (FSHD). BMD, LGMD, and FSHD were classified as slowly progressive MD. The results demonstrated that the Brooke scale was acceptable for grading arm function in DMD, but was unable to discriminate between differing levels of severity in slowly progressive MD. The floor effect was large for all types of slowly progressive MD (range, 20.0-61.9), and was especially high for BMD. The floor effect was also large for BMD (23.8%) and FSHD (50.0%) using the Vignos scale. Grades 6-8 of the Vignos scale were inapplicable because they included items involving the use of long leg braces for walking or standing, and some patients did not use long leg braces. In the Barthel Index, a ceiling effect was prominent for slowly progressive MD (58.9%), while a floor effect existed for DMD (17.9%). Among the slowly progressive MDs, FSHD patients had the best level of functioning; they had better leg function and their daily living activities were less affected than patients with other forms of slowly progressive MD. The results of this study demonstrate the acceptability of the different applications used for measuring functional status in patients with different types of MD. Some of the limitations of these measures as applied to MD should be carefully considered, especially in patients with slowly progressive MD. We suggest that these applications be used in combination with other measures, or that a complicated instrument capable of evaluating the various levels of functional status be used.

Entities:  

Mesh:

Year:  2009        PMID: 19560997     DOI: 10.1016/S1607-551X(09)70523-6

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  9 in total

Review 1.  Optimizing Bone Health in Duchenne Muscular Dystrophy.

Authors:  Jason L Buckner; Sasigarn A Bowden; John D Mahan
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

2.  Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies.

Authors:  Jérémy Rouillon; Jérôme Poupiot; Aleksandar Zocevic; Fatima Amor; Thibaut Léger; Camille Garcia; Jean-Michel Camadro; Brenda Wong; Robin Pinilla; Jérémie Cosette; Anna M L Coenen-Stass; Graham Mcclorey; Thomas C Roberts; Matthew J A Wood; Laurent Servais; Bjarne Udd; Thomas Voit; Isabelle Richard; Fedor Svinartchouk
Journal:  Hum Mol Genet       Date:  2015-06-09       Impact factor: 6.150

3.  Autonomic Modulation in Duchenne Muscular Dystrophy during a Computer Task: A Prospective Control Trial.

Authors:  Mayra Priscila Boscolo Alvarez; Talita Dias da Silva; Francis Meire Favero; Vitor Engrácia Valenti; Rodrigo Daminello Raimundo; Luiz Carlos Marques Vanderlei; David M Garner; Carlos Bandeira de Mello Monteiro
Journal:  PLoS One       Date:  2017-01-24       Impact factor: 3.240

4.  The cardiorespiratory response and physiological determinants of the assisted 6-minute handbike cycle test in adult males with muscular dystrophy.

Authors:  Christopher I Morse; Emma L Bostock; Harriet M Twiss; Laura H Kapp; Paul Orme; Matthew F Jacques
Journal:  Muscle Nerve       Date:  2018-05-17       Impact factor: 3.217

5.  Frequency of reported pain in adult males with muscular dystrophy.

Authors:  Matthew F Jacques; Rachel C Stockley; Emma I Bostock; Jonathon Smith; Christian G DeGoede; Christopher I Morse
Journal:  PLoS One       Date:  2019-02-14       Impact factor: 3.240

6.  Inspiratory muscle training in children and adolescents living with neuromuscular diseases: A pre-experimental study.

Authors:  Anri Human; Brenda M Morrow
Journal:  S Afr J Physiother       Date:  2021-08-31

7.  Objective and subjective measures of sleep in men with Muscular Dystrophy.

Authors:  Christopher I Morse; Gladys Onambele-Pearson; Bryn Edwards; Sze Choong Wong; Matthew F Jacques
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

8.  Altered Tnnt3 characterizes selective weakness of fast fibers in mice overexpressing FSHD region gene 1 (FRG1).

Authors:  Valentina Sancisi; Elena Germinario; Alessandra Esposito; Elisabetta Morini; Samantha Peron; Maurizio Moggio; Giuliano Tomelleri; Daniela Danieli-Betto; Rossella Tupler
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-12-04       Impact factor: 3.619

9.  Multi-slice MRI reveals heterogeneity in disease distribution along the length of muscle in Duchenne muscular dystrophy.

Authors:  Stephen M Chrzanowski; Celine Baligand; Rebecca J Willcocks; Jasjit Deol; Ilona Schmalfuss; Donovan J Lott; Michael J Daniels; Claudia Senesac; Glenn A Walter; Krista Vandenborne
Journal:  Acta Myol       Date:  2017-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.